Table 2.
Cardiac biomarkers and risk of all‐cause mortality
| Total mortality | ||
|---|---|---|
| HR (95% CI) | P‐value | |
| Cystatin C (n = 258; 56 events) | ||
| Model 1 | 1.99 (1.52–2.62) | 5.8 × 10−7 |
| Model 2 | 2.11 (1.56–2.86) | 1.0 × 10−6 |
| NT‐proBNP (n = 262; 55 events) | ||
| Model 1 | 1.88 (1.37–2.57) | 8.2 × 10−5 |
| Model 2 | 1.85 (1.32–2.61) | 4.0 × 10−4 |
| Copeptin (n = 259; 57 events) | ||
| Model 1 | 1.63 (1.20–2.20) | 0.002 |
| Model 2 | 1.70 (1.22–2.36) | 0.002 |
| MR‐proADM (n = 250; 53 events) | ||
| Model 1 | 1.78 (1.32–2.41) | 1.9 × 10−4 |
| Model 2 | 1.94 (1.36–2.75) | 2.2 × 10−4 |
| CT‐pro‐ET‐1 (n = 260; 57 events) | ||
| Model 1 | 1.45 (1.08–1.95) | 0.014 |
| Model 2 | 1.42 (1.03–1.95) | 0.034 |
CI, confidence interval; CT‐pro‐ET‐1, C‐terminal pro‐endothelin‐1; HR, hazard ratio; MR‐proADM, mid‐regional pro‐adrenomedullin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Cox regressions: Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, body mass index, diabetes status, smoking, atrial fibrillation, systolic blood pressure at admission, total cholesterol, high‐density lipoprotein, and New York Heart Association class at admission.